[New antimicrobial agent series XL: arbekacin].
Niijima
T
T
D000617:Aminoglycosides; D000818:Animals; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D003982:Dibekacin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006801:Humans; D066298:In Vitro Techniques; D016106:Methicillin Resistance; D051379:Mice; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D003982:Dibekacin; C031986:arbekacin